Partager
Annuaire
Vous êtes ici : Version françaiseAnnuaire

Personnel hébergé

M. Denis Mulleman

Main duties and past experience in my research Research unit - Coordinator of the Consortium «Monitoring of monoclonal Antibodies Group in Europe» (MAGE) for inflammatory diseases (Mai 2015-December 2017). The MAGE Consortium is supported by LE STUDIUM Loire Valley Institute for Advanced Studies (http://www.lestudium-ias.com/) - Representative in the ABIRISK consortium (www.abirisk.eu) dedicated to immunogenicity to biopharmaceutical March 2012-March 2018 - co-leader of the key question N°3 of the Laboratory of Excellence MabImprove (“How can antibodies efficacy can be increased using combination) with Laurent Gros (Inserm (http://mabimprove.univ-tours.fr/en/) (December 2017-present) - Guest researcher at the University of Uppsala (Siv Jönsson and Mats Karlsson) at the department of pharmacometrics (sept 2019-August 2020) - Chair of the COST Action ENOTTA (https://www.cost.eu/actions/CA21147/) European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases (November 2022-November 2026)

Coordonnées

10 Boulevard Tonnellé 37032 TOURS CEDEX 1 Avenue de la République 37170 CHAMBRAY LES TOURS

Tél
0247366368
Mail
denis.mulleman@univ-tours.fr
Site internet
https://nmns.univ-tours.fr/accueil/home/home

Discipline(s)

Rhumatologie

Thèmes de recherche

Key words:
Biopharmaceuticals, Advanced therapy medicinal product, monoclonal antibodies, cellular response, therapeutic drug monitoring, immunogenicity, quantitative systems pharmacology, inflammatory rheumatic diseases

Activités / CV

Clinical studies:
  1. Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA) NCT00497614 (Principal Investigator)
  2. Pharmaco Kinetic Variability of Infliximab in Rheumatoid Arthritis (FAKIR) NCT00840957 (Principal Investigator)
  3. Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA) NCT01382160 (Principal Investigator)
  4. Combinaison of Methotrexate to Adalimumab to Reduce Immunization in ankylosing Spondylitis (CoMARIS) NCT01895764 (Co-Investigator)
  5. Relationship between T LYmphocytes depletion and clinical response to RITUXimab in rheumatoid arthritis (LYRITUX) NCT02304354 (Co-Investigator)
  6. Effect of a new BI-specific antibody towards dendritic Cells on inflammation in Rheumatoid Arthritis (BIC-RA) NCT03416543 (Principal Investigator)

Informations complémentaires